KYNB

+ Watchlist + Portfolio

Kyntra Bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.15
52-Week Range: $6.32 – $12.60
Market Cap: $29.64M
P/E (TTM): —
EPS (TTM): -7.64
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -22.50%
Gross Margin: 0.00%
Operating Margin: 1191.52%
Profit Margin: 3968.63%
Current Ratio: 2.69
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $54.07M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-40.37M

KYNB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$140.73M	$46.80M	$29.62M	$6.44M
Cost of Revenue	$20.28M	$3.96M	$15.56M	$556.00K
Gross Profit	$120.45M	$42.84M	$14.06M	$5.88M
Research & Development	$296.79M	$266.47M	$95.69M	$23.52M
Selling, General & Admin	$124.69M	$86.48M	$49.33M	$27.71M
Operating Expenses	$421.48M	$352.96M	$145.02M	$51.23M
Operating Income	-$301.02M	-$310.12M	-$130.96M	-$45.34M
EBITDA	-$282.82M	-$305.20M	-$142.43M	-$48.79M
Pretax Income	-$294.87M	-$323.22M	-$153.37M	-$58.29M
Income Tax	$358.00K	-$252.00K	-$269.00K	-$90.00K
Net Income	-$293.65M	-$284.23M	-$47.58M	$183.45M
Diluted EPS	-78.50	-73.00	-12.00	45.37
Diluted Shares	3.74M	3.89M	4.00M	4.04M

KYNB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$155.70M	$81.55M	$50.48M	$47.87M
Receivables	$16.30M	$33.62M	$28.98M	$4.22M
Inventory	$40.44M	$17.17M	$3.15M	$3.74M
Current Assets	$492.83M	$331.56M	$196.51M	$99.07M
Total Assets	$610.09M	$423.53M	$214.53M	$119.59M
Current Liabilities	$273.56M	$217.67M	$133.31M	$29.24M
Long-Term Debt	—	$71.93M	$73.09M	—
Total Debt	$89.89M	$149.61M	$73.09M	—
Total Liabilities	$611.57M	$585.73M	$398.16M	$115.12M
Retained Earnings	-$1.56B	-$1.84B	-$1.89B	-$1.71B
Shareholders' Equity	-$21.45M	-$204.17M	-$225.60M	-$30.04M
Working Capital	$219.26M	$113.89M	$63.20M	$69.83M
Net Debt	—	—	$22.61M	—

KYNB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$145.93M	-$315.02M	-$138.00M	-$4.77M
Capital Expenditure	-$38.74M	-$2.52M	-$266.00K	-$38.00K
Free Cash Flow	-$184.67M	-$317.54M	-$138.26M	-$4.81M
Depreciation & Amortisation	$10.60M	$9.93M	$2.69M	$748.00K
Stock-Based Compensation	$65.60M	$50.77M	$25.21M	$6.58M
Investing Cash Flow	$89.12M	$153.66M	$125.99M	$35.42M
Financing Cash Flow	$46.78M	$122.75M	-$255.00K	-$86.03M
Net Change in Cash	-$10.04M	-$38.62M	-$12.26M	-$55.38M

KYNB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.74M	$1.35M	$1.08M	$1.28M	$3.74M
Cost of Revenue	$252.00K	$85.00K	-$58.00K	$278.00K	$4.11M
Gross Profit	$2.49M	$1.26M	$1.13M	$999.00K	-$368.00K
Research & Development	$9.18M	$5.87M	$1.21M	$7.27M	$7.57M
Selling, General & Admin	$8.11M	$7.06M	$5.29M	$7.25M	$5.86M
Operating Expenses	$17.28M	$12.92M	$6.50M	$14.52M	$13.43M
Operating Income	-$14.79M	-$11.66M	-$5.37M	-$13.52M	-$13.80M
EBITDA	-$14.18M	-$11.54M	-$10.87M	-$12.19M	-$12.70M
Pretax Income	-$16.76M	-$13.78M	-$13.15M	-$14.61M	-$15.13M
Income Tax	$2.00K	-$92.00K	$0.00	$0.00	$0.00
Net Income	$4.64M	-$7.60M	$200.64M	-$14.22M	-$15.20M
Diluted EPS	1.15	-1.88	49.61	-3.51	-3.76
Diluted Shares	4.04M	4.04M	4.04M	4.05M	4.05M

KYNB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$33.61M	$23.37M	$117.97M	$47.87M	$37.00M
Receivables	$147.00K	$136.00K	$10.12M	$4.22M	$9.04M
Inventory	$3.15M	$3.86M	$3.86M	$3.74M	$3.38M
Current Assets	$148.53M	$162.32M	$133.42M	$99.07M	$101.36M
Total Assets	$165.21M	$178.06M	$137.01M	$119.59M	$109.63M
Current Liabilities	$73.39M	$155.90M	$35.97M	$29.24M	$28.11M
Long-Term Debt	$73.42M	—	—	—	—
Total Debt	$73.42M	$73.73M	—	—	—
Total Liabilities	$340.14M	$359.08M	$119.53M	$115.12M	$118.92M
Retained Earnings	-$1.88B	-$1.89B	-$1.69B	-$1.71B	-$1.72B
Shareholders' Equity	-$216.90M	-$223.00M	-$17.03M	-$30.04M	-$43.80M
Working Capital	$75.14M	$6.43M	$97.45M	$69.83M	$73.24M
Net Debt	$39.81M	$50.37M	—	—	—

KYNB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$2.72M	$12.68M	-$1.85M	-$18.33M	-$13.89M
Capital Expenditure	-$16.00K	-$13.00K	-$9.00K	—	—
Free Cash Flow	$2.70M	$12.67M	-$1.86M	-$18.33M	-$13.89M
Depreciation & Amortisation	$327.00K	$221.00K	$192.00K	$8.00K	$7.00K
Stock-Based Compensation	$2.85M	$1.87M	$662.00K	$1.19M	$1.15M
Investing Cash Flow	-$16.00K	-$13.00K	$87.16M	-$51.71M	$3.02M
Financing Cash Flow	-$88.00K	-$9.00K	-$85.92M	-$14.00K	-$7.00K
Net Change in Cash	$2.62M	$12.66M	-$604.00K	-$70.05M	-$10.88M

Market Snapshot

About

Kyntra Bio, Inc. is a biotechnology company developing novel treatments for inflammatory bowel disease (IBD) and other inflammatory conditions. The company's lead programs focus on developing selective antibodies that target specific pathways involved in chronic inflammation. Kyntra's therapeutic candidates aim to provide more targeted and effective treatments for patients with Crohn's disease, ulcerative colitis, and related autoimmune disorders.